Anixa Biosciences Inc.

3.13-0.0800-2.49%Vol 48.83K1Y Perf -18.73%
Jun 24th, 2022 16:00 DELAYED
BID3.05 ASK3.30
Open3.25 Previous Close3.21
Pre-Market- After-Market3.28
 - -  0.15 4.79%
Target Price
11.00 
Analyst Rating
Strong Buy 1.00
Potential %
251.44 
Finscreener Ranking
★★★★★     60.24
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★★     56.31
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★+     55.03
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
23.25 
Earnings Rating
Buy
Market Cap95.37M 
Earnings Date
9th Jun 2022
Alpha0.05 Standard Deviation0.42
Beta1.41 

Today's Price Range

3.083.29

52W Range

2.305.87

5 Year PE Ratio Range

-4.20-7.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
0.64%
1 Month
-11.33%
3 Months
12.19%
6 Months
-1.57%
1 Year
-18.73%
3 Years
-14.71%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANIX3.13-0.0800-2.49
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
27.10
27.40
0.01
0.01
-
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
100.40
3.19M
3.18M
-2 757.80
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-2.49
-49.20
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.13-0.127.69
Q01 2022-0.13-0.130.00
Q03 2021-0.08-0.14-75.00
Q01 2021-0.11-0.0918.18
Q04 2020--0.81-
Q03 2020-0.12-0.118.33
Q02 2020--0.12-
Q01 2020-0.13-0.130.00
Earnings Per EndEstimateRevision %Trend
7/2022 QR-0.130.00-
10/2022 QR-0.130.00-
10/2022 FY-0.520.00-
10/2023 FY-0.610.00-
Next Report Date-
Estimated EPS Next Report-0.13
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume48.83K
Shares Outstanding30.47K
Shares Float29.02M
Trades Count363
Dollar Volume154.40K
Avg. Volume88.57K
Avg. Weekly Volume52.44K
Avg. Monthly Volume124.16K
Avg. Quarterly Volume89.12K

Anixa Biosciences Inc. (NASDAQ: ANIX) stock closed at 3.13 per share at the end of the most recent trading day (a -2.49% change compared to the prior day closing price) with a volume of 48.83K shares and market capitalization of 95.37M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 4 people. Anixa Biosciences Inc. CEO is Amit Kumar.

The one-year performance of Anixa Biosciences Inc. stock is -18.73%, while year-to-date (YTD) performance is 5.39%. ANIX stock has a five-year performance of %. Its 52-week range is between 2.3 and 5.87, which gives ANIX stock a 52-week price range ratio of 23.25%

Anixa Biosciences Inc. currently has a PE ratio of -6.00, a price-to-book (PB) ratio of 2.95, a price-to-sale (PS) ratio of 192.85, a price to cashflow ratio of 18.90, a PEG ratio of 2.32, a ROA of -47.23%, a ROC of -44.76% and a ROE of -48.25%. The company’s profit margin is -%, its EBITDA margin is 3 176 570.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Anixa Biosciences Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Anixa Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Anixa Biosciences Inc. is Strong Buy (1), with a target price of $11, which is +251.44% compared to the current price. The earnings rating for Anixa Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anixa Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anixa Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.67, ATR14 : 0.28, CCI20 : -72.77, Chaikin Money Flow : -0.13, MACD : -0.05, Money Flow Index : 45.06, ROC : -9.54, RSI : 44.82, STOCH (14,3) : 12.44, STOCH RSI : 0.18, UO : 46.32, Williams %R : -87.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anixa Biosciences Inc. in the last 12-months were: Amit Kumar (Buy at a value of $130 340), Arnold Baskies (Buy at a value of $160 270), Emily Gottschalk (Buy at a value of $79 457), Lewis H. Titterton (Buy at a value of $451 607), Michael J. Catelani (Buy at a value of $20 978)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Anixa Biosciences Inc.

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.

CEO: Amit Kumar

Telephone: +1 408 708-9808

Address: 3150 Almaden Expressway, San Jose 95118, CA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

62%38%

Bearish Bullish

56%44%

News

Stocktwits